ELUT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EL

Mkt Cap

$34.9M

Volume

86.31K

Next Earnings

November 5th

Loading chart

EL

ELUTElutia Inc. Class A Common Stock

ELUT

Pay with—

Available Balance0.00

EL

Mkt Cap

$34.9M

Volume

86.31K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)Elutia Inc. (Nasdaq: ELUT) announced the grant of 460,000 non-qualified stock options to three new employees as inducement awards on March 10, 2026, with an exercise price of $1.09 per share. The options vest 25% after one year, with the remainder vesting monthly over three years, subject to continued employment.GlobeNewswire Inc. · Mar 13, 2026

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 MillionElutia sold its BioEnvelope business to Boston Scientific for $88 million, allowing the company to focus on developing NXT-41x, a biomatrix technology for breast reconstruction with potential to address serious surgical complications.Benzinga · Oct 1, 2025

Zacks.com featured highlights BRC, Costamare and ElutiaBRC, Costamare and Elutia have been highlighted in this Screen of The Week article.Zacks Investment Research · Jun 27, 2024

3 Best Breakout Stocks Worth a Buy for Attractive ReturnsBRC (BRCC), Costamare (CMRE) and Elutia (ELUT) have been selected as the breakout stocks for today.Zacks Investment Research · Jun 26, 2024

Elutia Announces $13.26 Million Registered Direct OfferingSILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company’s Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $13.26 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about June 18, 2024, subject to customary closing conditions.GlobeNewswire Inc. · Jun 17, 2024

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and DefibrillatorsEluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection marketGlobeNewswire Inc. · Jun 17, 2024

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1SILVER SPRING, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024, at 3:00 p.m. ET (12:00 p.m. PT).GlobeNewswire Inc. · Apr 24, 2024

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.GlobeNewswire Inc. · Feb 22, 2024

Elutia Regains Compliance with Nasdaq Listing RequirementsSILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq’s market value of listed securities requirement and majority independent board requirement. As a result, the Company now satisfies all applicable requirements for continued listing with Nasdaq, and the Company’s Class A common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “ELUT.”GlobeNewswire Inc. · Jan 10, 2024

Elutia Inc. (ELUT) Upgraded to Buy: Here's WhyElutia Inc. (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).Zacks Investment Research · Nov 17, 2023

to start trading

EL

ELUTElutia Inc. Class A Common Stock

ELUT

Pay with—

Available Balance0.00

Your PositionYou don't own any ELUT yet.

Related Tickers

Earnings